



Canadian
Cancer
Society

Applicant Institution Title	Award
Cescon, David University Health Network <i>Novel cell-free DNA assays to predict relapse and guide systemic therapy in early breast cancer</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Davey, Scott Queen's University <i>A functional approach to assessing variants of unknown significance in BRCA1 carriers</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Godbout, Roseline University of Alberta <i>Targeting p53-mutated triple-negative breast cancer: role of nuclear factor IB</i>	2017/2018 : \$149,920 2018/2019 : \$149,920 2019/2020 : \$149,920
Gunning, Patrick University of Toronto <i>Small molecules targeting aberrant STAT3 activity in breast cancer: killing breast tumour cells and inducing anti-tumour immune response</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Johnston, Brent Dalhousie University <i>Targeting breast cancer via combined natural killer T cell immunotherapy and oncolytic virotherapy</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Khokha, Rama University Health Network <i>Rationalized depletion of mammary progenitors as a program for breast cancer prevention</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Kotsopoulos, Joanne Women's College Hospital <i>Delineating a role of RANKL/OPG-signalling on breast cancer development</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$149,650



Applicant Institution Title	Award
Lee, Jonathan University of Ottawa <i>Control of breast cancer by cooperation between the PI4KIIIIB lipid kinase and the Rab11a GTPase</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$149,919
Lohrisch, Caroline BC Cancer Agency <i>LA LEAST. Luminal A, Limited Endocrine Adjuvant Systemic Therapy, a phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer</i>	2017/2018 : \$150,000 2018/2019 : \$150,000 2019/2020 : \$150,000
Metcalf, Kelly University of Toronto <i>Breast cancer treatment in women with PALB2 mutations</i>	2017/2018 : \$149,071 2018/2019 : \$146,637 2019/2020 : \$149,481
Nielsen, Torsten Vancouver General Hospital <i>Clinical utility of immune response biomarkers for aggressive breast cancers</i>	2017/2018 : \$149,343 2018/2019 : \$149,848 2019/2020 : \$149,446
Ross, Colin University of British Columbia <i>Pharmacogenomic discovery of predictive cardiotoxicity biomarkers in breast cancer patients receiving anthracycline chemotherapies</i>	2017/2018 : \$148,942 2018/2019 : \$147,353 2019/2020 : \$148,230
Shepherd, Lois Queen's University <i>Quantitative standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) for prognostic and/or predictive index for response to adjuvant aromatase inhibitors exemestane or anastrozole</i>	2017/2018 : \$59,300 2018/2019 : \$80,111 2019/2020 : \$5,000
Whelan, Timothy McMaster University <i>Prospective cohort study evaluating risk of local recurrence following breast conserving surgery alone in low risk luminal A breast cancer</i>	2017/2018 : \$115,183 2018/2019 : \$101,272 2019/2020 : \$118,391